🔗 Share this article

As the US continues making sweeping adjustments to its vaccine guidelines, one figure appears somewhat surprisingly: Tracy Beth Høeg, a US-based sports physician and epidemiologist who first made her name by casting doubt on Covid vaccines during the pandemic and has concentrated on possible fatalities following Covid vaccination in her recent time at the Food and Drug Administration.

Scheduled Changes to Pediatric Vaccine Program

Agency leaders had intended to unveil major revisions to the pediatric vaccine schedule recently, aligning the US with Denmark’s national calendar, according to reports – a significant shift that would place the US out of alignment with much of the international standard with no evidence for improved outcomes. This reveal has been delayed until the coming year.

In place of Vinay Prasad, Tracy Beth Høeg is listed to present at the event. She was just designated acting director of the FDA’s CDER, the fifth individual to lead the division this calendar year.

A Shift at the Regulatory Body

The acting appointment might represent a tighter collaboration between the drug and biologics centers as Høeg and Prasad strengthen their influence at the FDA – and it suggests a renewed priority upon rolling back previously authorized vaccines at the FDA.

The new acting director has repeatedly called for discontinuing specific childhood immunization guidelines in the US so as to align more similar to Denmark, a nation with comprehensive healthcare and a citizenry about the size of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on vaccination policy – typically the responsibility of Dr. Prasad, head of the FDA’s CBER – as opposed to drug regulation.

Questions Over Expertise

The appointee has little discernible track record in drug development, oversight or administrative roles, which has been typical for previous leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the commissioner and the vaccine center since earlier this year.

“She doesn’t seem to have the necessary background” for leading the drug-regulation department, stated Dr. Jonathan Howard. “She’s never run a clinical trial. She has no expertise in leading a sizeable institution. She lacks background in drug approvals.”

Past directors of the center would “grasp regulatory frameworks and the research of pharmaceutical innovation”, noted a former acting FDA commissioner. “Frankly, she doesn’t have the sort of resume that previous people who led CBER have had.”

This division has an immense workload at the agency, she stated.

“The public just pays attention on the novel medication approvals, but the generic drug division authorizes numerous generic drugs. There is also a biosimilars division, over-the-counter program and other areas, and each of these have to be managed,” Dr. Woodcock explained. “The responsibility you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Furthermore, a significant leadership element to the role, which manages more than 5,000 employees. “It is a massive management job, if you execute it properly,” she added.

Response and Disputed Policies

When asked about inquiries about Høeg’s fitness for the role and whether this appointment signifies increased cooperation among regulatory chiefs on vaccines, a representative said that the “concerns are based on flawed assumptions”.

“Her experience aligns with the duties of her position,” the representative explained, noting the time Dr. Høeg spent advising the FDA commissioner on “medication safety and oversight research, including computational safety modeling and shot safety tracking”.

In her interim role, Høeg inherits the agency head's new expedited review system, a controversial rapid therapy clearance system that allegedly troubled her predecessors. “How are these medications being picked for this expedited pathway? Who takes the decisions?” Dr. Howard questioned. “There is a lot of confidentiality happening at the agency right now.”

In general, he stated, “the Food and Drug Administration appears to be shifting towards more relaxed rules of most medications, aside from immunizations.”

Documented Track Record on Immunizations

Regarding immunizations, Dr. Høeg has a clearer, if problematic, track record, critics observe. She released a analysis using unverified public submissions to assess the rate of heart inflammation following COVID-19 vaccination. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccines are riskier than they are.

Part of her “wish list” for the new federal leadership included changing regulations for new vaccines and discontinuing “non-essential” immunizations, she stated post-election on a podcast. At the agency, Dr. Høeg has reportedly floated the idea of excluding young men from obtaining COVID-19 vaccines.

“She is an all-around ideologue who begins with her conclusions and tailors the evidence to accommodate the evidence in a very deceptive, fraudulent manner,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg aligned with fellow skeptics, {like|